| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 12/13/2001 | WO2001093913A2 T cell receptor fusions and conjugates and methods of use thereof |
| 12/13/2001 | WO2001093911A2 Macromolecular drug complexes and compositions containing the same |
| 12/13/2001 | WO2001093890A2 Botulinum toxin implant |
| 12/13/2001 | WO2001093885A1 Therapeutic agents - ii |
| 12/13/2001 | WO2001093884A1 Therapeutic agents - i |
| 12/13/2001 | WO2001093883A1 Therapeutic agents - iii |
| 12/13/2001 | WO2001093881A1 Immunological substance containing enteroabsorbable anti-inflammatory factor and application thereof |
| 12/13/2001 | WO2001093879A1 Biologically active agents and drugs |
| 12/13/2001 | WO2001093862A1 Prostaglandin compounds for treating congestive heart failure |
| 12/13/2001 | WO2001093861A1 Tissue specific prodrug |
| 12/13/2001 | WO2001093860A1 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| 12/13/2001 | WO2001093859A1 Stable pharmaceutical product and formulation |
| 12/13/2001 | WO2001093857A1 Composition for pain mediation and apparatus and method of use thereof |
| 12/13/2001 | WO2001093853A1 Management of snoring by oral administration of dimethyl sulfone |
| 12/13/2001 | WO2001093836A2 Encapsulation of polynucleotides and drugs into targeted liposomes |
| 12/13/2001 | WO2001093835A1 Delivery systems for bioactive agents |
| 12/13/2001 | WO2001093833A2 Kits and methods for optimizing the efficacy of chondroprotective compositions |
| 12/13/2001 | WO2001093831A2 Low carbohydrate compositions, kits thereof, and methods of use |
| 12/13/2001 | WO2001093830A1 Method for obtaining aqueous formulations of oxidation-sensitive active principles |
| 12/13/2001 | WO2001093829A2 Powder compositions |
| 12/13/2001 | WO2001093827A2 Neurotoxin implant |
| 12/13/2001 | WO2001093825A1 Storage-stable compositions of glycerol monoalkyl ethers |
| 12/13/2001 | WO2001093804A2 Hepatitis c virus conjugates |
| 12/13/2001 | WO2001070225A3 Oxazolidinone tablet formulation |
| 12/13/2001 | WO2001068140A3 Opioid formulations |
| 12/13/2001 | WO2001045668A3 Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
| 12/13/2001 | WO2001041735A3 Thermosensitive biodegradable hydrogels based on low molecular weight pluronics |
| 12/13/2001 | WO2001041550A3 Topical anesthetic formulation |
| 12/13/2001 | WO2001039742A3 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 12/13/2001 | WO2001039741A3 Mitomycin c solution |
| 12/13/2001 | WO2001037820A3 Ionizable indolinone derivatives and their use as ptk ligands |
| 12/13/2001 | WO2001037781A3 A stable aqueous dispersion of nutrients |
| 12/13/2001 | WO2001035929A3 Biodegradable polymer composition |
| 12/13/2001 | WO2001032852A3 Method for directed packaging of molecular substances in protein shells |
| 12/13/2001 | WO2001032139A3 Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained |
| 12/13/2001 | WO2001026637A3 Transdermal therapeutic system for administering acetylsalicylic acid and/or salicylic acid |
| 12/13/2001 | WO2001021157A3 Local delivery of 17-beta estradiol for preventing vascular intima hyperplasia and for improving vascular endothelium function after vascular injury |
| 12/13/2001 | WO2001021008A3 Method for increasing pet activity |
| 12/13/2001 | WO2001019362A3 Formulations for treating or preventing mucositis |
| 12/13/2001 | WO2001018181A3 Enzyme inhibitors |
| 12/13/2001 | WO2000078791A3 FUNCTIONAL POLY-α-AMINOACID DERIVATIVES USEFUL FOR THE MODIFICATION OF BIOLOGICALLY ACTIVE MATERIALS AND THEIR APPLICATION |
| 12/13/2001 | WO2000029008A9 Hiv-specific t-cell induction |
| 12/13/2001 | WO2000006194A9 Depletion of cells responsible for antibody-mediated graft rejection |
| 12/13/2001 | US20010051834 Method for composite cell-based implants |
| 12/13/2001 | US20010051717 Beta (1-3) -glucan diagnostic assays |
| 12/13/2001 | US20010051686 For sensitive skin, nonirritating; includes branched or crosslinked polyelectrolyte, comprising a salified strong acid monomer such as 2-acrylamido-2-methylpropanesulfonic acid sodium salt and acrylamide copolymer |
| 12/13/2001 | US20010051672 Dental material based on cationically polymerizable monomers |
| 12/13/2001 | US20010051650 Topical compositions comprising ascomycins |
| 12/13/2001 | US20010051613 Water solubility |
| 12/13/2001 | US20010051604 Mixture containing stabilizers, sodium chloride, buffer and surfactants |
| 12/13/2001 | US20010051603 Dried blood factor composition comprising trehalose |
| 12/13/2001 | US20010051595 Injection into blood |
| 12/13/2001 | US20010051348 Complexing |
| 12/13/2001 | US20010051187 Via crystallization upon exposure to pressure; for drug dosage via oral or nasal administration of free-flowing form |
| 12/13/2001 | US20010051184 Alcohol solubility |
| 12/13/2001 | US20010051183 Containing antibiotic/anticancer agent entrapped within vesicles; for treatment of breast and colon carcinomas; diagnostics; therapy; biocompatability |
| 12/13/2001 | US20010051166 Hydroxide-releasing agents as skin permeation enhancers |
| 12/13/2001 | US20010051154 Mixing with polysaccharide and amino acid |
| 12/13/2001 | US20010051144 Polymer transport system for active biological compounds |
| 12/13/2001 | US20010051140 Method for manufacturing pure guar meal |
| 12/13/2001 | EP1143806A3 Method for increasing pet activity |
| 12/13/2001 | DE10027887A1 Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen Compounds having a sulfonamide group, these compounds and pharmaceutical compositions containing them |
| 12/13/2001 | DE10027050A1 Therapeutic composition containing alginate preparation and plant extract, useful e.g. for immunomodulation or treatment of gastrointestinal disorders, migraine, rheumatism or diabetes |
| 12/13/2001 | DE10025609A1 Transfektionssystem Transfection |
| 12/13/2001 | DE10024069A1 Konjugat auf der Basis einer heterobifunktionalen Brückenverbindung, die mit einem Immunmodulator und einer zellerkennenden Einheit substituiert ist Conjugate on the basis of a heterobifunctional bridge connection, which is substituted with an immunomodulator and a cell recognizing unit |
| 12/13/2001 | CA2707766A1 Plasmids ptqomp and ptto-1 which have an ompa signal sequence |
| 12/13/2001 | CA2414076A1 Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| 12/13/2001 | CA2412326A1 Stabilized hmg-coa reductase inhibitor pharmaceutical compositions |
| 12/13/2001 | CA2412197A1 Powder compositions |
| 12/13/2001 | CA2411596A1 Therapeutic agents - ii |
| 12/13/2001 | CA2411542A1 Encapsulation of polynucleotides and drugs into targeted liposomes |
| 12/13/2001 | CA2411470A1 T cell receptor fusions and conjugates and methods of use thereof |
| 12/13/2001 | CA2410052A1 Delivery systems for bioactive agents |
| 12/13/2001 | CA2409287A1 Hepatitis c virus conjugates |
| 12/13/2001 | CA2409268A1 Macromolecular drug complexes and compositions containing the same |
| 12/13/2001 | CA2408611A1 Kits and methods for optimizing the efficacy of chondroprotective compositions |
| 12/13/2001 | CA2408610A1 Low carbohydrate compositions, kits thereof, and methods of use |
| 12/13/2001 | CA2408542A1 Prostaglandin compounds for treating congestive heart failure |
| 12/12/2001 | EP1161957A1 Complex for transferring an anionic substance of interest into a cell |
| 12/12/2001 | EP1161956A1 Medicinal compositions |
| 12/12/2001 | EP1161947A2 Oral antibacterial compositions and method for the improvement of gastrointestinal absorption of penem or carbapenem antibiotics |
| 12/12/2001 | EP1161480A1 Biodegradable and thermosensitive polyphosphazenes and their preparation method |
| 12/12/2001 | EP1161458A1 Malatyl polysaccharides, their production and their use |
| 12/12/2001 | EP1161456A2 Antibody and chemokine constructs and their use for treating autoimmune diseases |
| 12/12/2001 | EP1161452A2 Covalently bridged insulin dimers |
| 12/12/2001 | EP1161418A1 1-acyl-7-nitroindoline derivatives, their preparation and their use as photocleavable precursors |
| 12/12/2001 | EP1161264A1 Polymer compositions for polynucleotide delivery |
| 12/12/2001 | EP1161261A1 Apoptosis inducing molecule ii and methods of use |
| 12/12/2001 | EP1161259A1 Intranasal delivery of pneumococcal polysaccharide vaccines |
| 12/12/2001 | EP1161257A2 Pharmaceutical compositions comprising tgf-beta |
| 12/12/2001 | EP1161243A2 Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin |
| 12/12/2001 | EP1161241A1 Stable pharmaceutical application form for paroxetin anhydrate |
| 12/12/2001 | EP1161236A1 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors |
| 12/12/2001 | EP1161230A1 Transdermal therapy system and method for producing the same |
| 12/12/2001 | EP1161228A2 Composition comprising isoquercetin and ascorbic acid in a sustained release form |
| 12/12/2001 | EP1161226A1 Phosphocholine linked prodrug derivatives |
| 12/12/2001 | EP1161150A1 Therapeutic antimicrobial compositions |
| 12/12/2001 | EP1161147A1 Peptide mimics useful for treating disease |
| 12/12/2001 | EP1161146A1 Deep penetrating antimicrobial compositions |
| 12/12/2001 | EP1077688B1 Transdermal therapeutic system containing pergolide |